MicroRNA-130b promotes cell aggressiveness by inhibiting peroxisome proliferator-activated receptor gamma in human hepatocellular carcinoma

International Journal of Molecular Sciences

Volumn 15, Issue 11, 2014, Pages 20486-20499

  Tu, Kangsheng ^a   Zheng, Xin ^a   Dou, Changwei ^a   Li, Chao ^a   Yang, Wei ^a   Yao, Yingmin ^a   Liu, Qingguang ^a  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Invasion; MicroRNA 130b; PPAR (peroxisome proliferator activated receptor gamma); Tumor metastasis

Indexed keywords

MICRORNA; MICRORNA 130B; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; MIRN130 MICRORNA, HUMAN;

ADULT; ARTICLE; CANCER GRADING; CANCER STAGING; CELL AGGRESSIVENESS; CELL FUNCTION; CELL INVASION; CELL MIGRATION; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; CELL MOTION; GENE EXPRESSION REGULATION; GENETICS; LIVER; LIVER TUMOR; METABOLISM; PATHOLOGY; TUMOR CELL LINE; TUMOR INVASION;

CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MICRORNAS; NEOPLASM INVASIVENESS; PPAR GAMMA;

EID: 84910147424     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms151120486     Document Type: Article

References (35)

1. Garzon, R.; Calin, G.A.; Croce, C.M. MicroRNAs in Cancer. Annu. Rev. Med. 2009, 60, 167-179.
2. Rosa, A.; Brivanlou, A.H. MicroRNAs in early vertebrate development. Cell Cycle 2009, 8, 3513-3520.
3. Harfe, B.D. MicroRNAs in vertebrate development. Curr. Opin. Genet. Dev. 2005, 15, 410-415.
4. Vasudevan, S.; Tong, Y.; Steitz, J.A. Switching from repression to activation: microRNAs can up-regulate translation. Science 2007, 318, 1931-1934.
5. Croce, C.M.; Calin, G.A. miRNAs, cancer, and stem cell division. Cell 2005, 122, 6-7.
6. Lu, J.; Getz, G.; Miska, E.A.; Alvarez-Saavedra, E.; Lamb, J.; Peck, D.; Sweet-Cordero, A.; Ebert, B.L.; Mak, R.H.; Ferrando, A.A., et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435, 834-838.
7. Calin, G.A.; Croce, C.M. MicroRNA signatures in human cancers. Nat. Rev. Cancer 2006, 6, 857-866.
8. Jansson, M.D.; Lund, A.H. MicroRNA and cancer. Mol. Oncol. 2012, 6, 590-610.
9. Wang, W.; Peng, B.; Wang, D.; Ma, X.; Jiang, D.; Zhao, J.; Yu, L. Human tumor microRNA signatures derived from large-scale oligonucleotide microarray datasets. Int. J. Cancer 2011, 129, 1624-1634.
10. Yip, L.; Kelly, L.; Shuai, Y.; Armstrong, M.J.; Nikiforov, Y.E.; Carty, S.E.; Nikiforova, M.N. MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma. Ann. Surg. Oncol. 2011, 18, 2035-2041.
11. Dong, P.; Karaayvaz, M.; Jia, N.; Kaneuchi, M.; Hamada, J.; Watari, H.; Sudo, S.; Ju, J.; Sakuragi, N. Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis. Oncogene 2013, 32, 3286-3295.
12. Leone, V.; Langella, C.; D’Angelo, D.; Mussnich, P.; Wierinckx, A.; Terracciano, L.; Raverot, G.; Lachuer, J.; Rotondi, S.; Jaffrain-Rea, M.L., et al. Mir-23b and miR-130b expression is downregulated in pituitary adenomas. Mol. Cell Endocrinol. 2014, 390, 1-7.
13. Zhao, G.; Zhang, J.G.; Shi, Y.; Qin, Q.; Liu, Y.; Wang, B.; Tian, K.; Deng, S.C.; Li, X.; Zhu, S., et al. MiR-130b is a prognostic marker and inhibits cell proliferation and invasion in pancreatic cancer through targeting STAT3. PLoS One 2013, 8, e73803.
14. Sand, M.; Skrygan, M.; Sand, D.; Georgas, D.; Gambichler, T.; Hahn, S.A.; Altmeyer, P.; Bechara, F.G. Comparative microarray analysis of microRNA expression profiles in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases, and benign melanocytic nevi. Cell Tissue Res. 2013, 351, 85-98.
15. Lai, K.W.; Koh, K.X.; Loh, M.; Tada, K.; Subramaniam, M.M.; Lim, X.Y.; Vaithilingam, A.; Salto-Tellez, M.; Iacopetta, B.; Ito, Y., et al. MicroRNA-130b regulates the tumour suppressor RUNX3 in gastric cancer. Eur. J. Cancer 2010, 46, 1456-1463.
16. Kim, B.H.; Hong, S.W.; Kim, A.; Choi, S.H.; Yoon, S.O. Prognostic implications for high expression of oncogenic microRNAs in advanced gastric carcinoma. J. Surg. Oncol. 2013, 107, 505-510.
17. Scheffer, A.R.; Holdenrieder, S.; Kristiansen, G.; von Ruecker, A.; Muller, S.C.; Ellinger, J. Circulating microRNAs in serum: Novel biomarkers for patients with bladder cancer? World J. Urol. 2014, 32, 353-358.
18. Colangelo, T.; Fucci, A.; Votino, C.; Sabatino, L.; Pancione, M.; Laudanna, C.; Binaschi, M.; Bigioni, M.; Maggi, C.A.; Parente, D., et al. MicroRNA-130b promotes tumor development and is associated with poor prognosis in colorectal cancer. Neoplasia 2013, 15, 1218-1231.
19. Wu, X.; Weng, L.; Li, X.; Guo, C.; Pal, S.K.; Jin, J.M.; Li, Y.; Nelson, R.A.; Mu, B.; Onami, S.H., et al. Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosis. PLoS One 2012, 7, e35661.
20. Kjersem, J.B.; Ikdahl, T.; Lingjaerde, O.C.; Guren, T.; Tveit, K.M.; Kure, E.H. Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment. Mol. Oncol. 2014, 8, 59-67.
21. Liu, A.M.; Yao, T.J.; Wang, W.; Wong, K.F.; Lee, N.P.; Fan, S.T.; Poon, R.T.; Gao, C.; Luk, J.M. Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: A retrospective cohort study. BMJ Open 2012, 2, doi:10.1136/bmjopen-2012-000825.
22. Kutay, H.; Bai, S.; Datta, J.; Motiwala, T.; Pogribny, I.; Frankel, W.; Jacob, S.T.; Ghoshal, K. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J. Cell Biochem. 2006, 99, 671-678.
23. Ma, S.; Tang, K.H.; Chan, Y.P.; Lee, T.K.; Kwan, P.S.; Castilho, A.; Ng, I.; Man, K.; Wong, N.; To, K.F., et al. miR-130b Promotes CD133+ liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell 2010, 7, 694-707.
24. Yang, M.-H.; Chen, C.-L.; Chau, G.-Y.; Chiou, S.-H.; Su, C.-W.; Chou, T.-Y.; Peng, W.-L.; Wu, J.-C. Comprehensive analysis of the independent effect of twist and snail in promoting metastasis of hepatocellular carcinoma. Hepatology 2009, 50, 1464-1474.
25. Ferlay, J.; Shin, H.R.; Bray, F.; Forman, D.; Mathers, C.; Parkin, D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010, 127, 2893-2917.
26. Petrelli, A.; Perra, A.; Cora, D.; Sulas, P.; Menegon, S.; Manca, C.; Migliore, C.; Kowalik, M.A.; Ledda-Columbano, G.M.; Giordano, S., et al. MicroRNA/gene profiling unveils early molecular changes and nuclear factor erythroid related factor 2 (NRF2) activation in a rat model recapitulating human hepatocellular carcinoma (HCC). Hepatology 2014, 59, 228-241.
27. Wang, W.Y.; Zhang, H.F.; Wang, L.; Ma, Y.P.; Gao, F.; Zhang, S.J.; Wang, L.C. High expression of microRNA-130b correlates with poor prognosis of patients with hepatocellular carcinoma. Diagn. Pathol. 2014, 9, doi:10.1186/s13000-014-0160-5.
28. Koeffler, H.P. Peroxisome proliferator-activated receptor gamma and cancers. Clin. Cancer Res. 2003, 9, 1-9.
29. Yu, J.; Qiao, L.; Zimmermann, L.; Ebert, M.P.; Zhang, H.; Lin, W.; Rocken, C.; Malfertheiner, P.; Farrell, G.C. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo. Hepatology 2006, 43, 134-143.
30. Shen, B.; Chu, E.S.; Zhao, G.; Man, K.; Wu, C.W.; Cheng, J.T.; Li, G.; Nie, Y.; Lo, C.M.; Teoh, N., et al. PPARγ inhibits hepatocellular carcinoma metastases in vitro and in mice. Br. J. Cancer 2012, 106, 1486-1494.
31. Lee, E.K.; Lee, M.J.; Abdelmohsen, K.; Kim, W.; Kim, M.M.; Srikantan, S.; Martindale, J.L.; Hutchison, E.R.; Kim, H.H.; Marasa, B.S., et al. miR-130 suppresses adipogenesis by inhibiting peroxisome proliferator-activated receptor gamma expression. Mol. Cell. Biol. 2011, 31, 626-638.
32. Tu, K.; Zheng, X.; Zan, X.; Han, S.; Yao, Y.; Liu, Q. Evaluation of Fbxw7 expression and its correlation with the expression of c-Myc, cyclin E and p53 in human hepatocellular carcinoma. Hepatol. Res. 2012, 42, 904-910.
33. Tu, K.; Yang, W.; Li, C.; Zheng, X.; Lu, Z.; Guo, C.; Yao, Y.; Liu, Q. Fbxw7 is an independent prognostic marker and induces apoptosis and growth arrest by regulating YAP abundance in hepatocellular carcinoma. Mol. Cancer 2014, 13, doi:10.1186/1476-4598-13-110.
34. Friedman, S.L. Mechanisms of disease: Mechanisms of hepatic fibrosis and therapeutic implications. Nat. Clin. Pract Gastroenterol. Hepatol. 2004, 1, 98-105.
35. Li, C.; Yang, W.; Zhang, J.; Zheng, X.; Yao, Y.; Tu, K.; Liu, Q. SREBP-1 has a prognostic role and contributes to invasion and metastasis in human hepatocellular carcinoma. Int. J. Mol. Sci. 2014, 15, 7124-7138.